Sponsor
Servier Laboratories
30 PBAC submissions on file, active 2005–2025. 50% have been recommended.
Submissions
30
2005 → 2025
Win rate
50 %
15 recommended of 30 bucketable
Drugs
10 · 6 listed
unique molecules submitted
PBS spend captured
—
FY-latest govt benefit on owned drugs
Drug portfolio
Sorted by PBS spend captured. PBS expenditure is credited to the sponsor with the most recent Recommended decision per drug, so biosimilars and originator brands aren't double-counted.
Therapy area mix Oncology 12 Cardiovascular 7 Endocrinology 6 Mental health 4 Musculo-skeletal 1
Activity by year 2005 (1) · 2006 (1) · 2007 (2) · 2008 (1) · 2009 (1) · 2010 (2) · 2011 (2) · 2012 (3) · 2014 (1) · 2015 (3) · 2016 (1) · 2017 (3) · 2018 (2) · 2019 (1) · 2024 (5) · 2025 (1)
Rejection patterns
Across 15 Not recommended decisions on file.
4× High and uncertain ICER2× modest clinical benefit in context of substantial toxicity1× Superiority of NALIRIFOX over FOLFIRINOX not adequately established by indirect evidence1× concerns regarding reliability of indirect treatment comparisons due to transitivity violations and differences between GENERATE and NAPOLI-3 trials1× uncertain clinical meaningfulness of OS improvement over Gem+NabP (1.9 months)Open on full dashboard →
Part of script.report — an independent tracker of every PBAC Public Summary Document and the PBS expenditure that follows. Built from public data on pbs.gov.au . Not affiliated with the Australian Department of Health, PBAC, or any pharmaceutical company.
script.report extracts information discussed in PBAC Public Summary Documents (PSDs), not independently calculated values. Where figures such as ICERs are shown, they reflect what was discussed or referenced in committee documentation — not confirmed inputs. For authoritative cost-effectiveness data, refer to the original PSD.